Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 31, 2015 8:36 PM ET

Biotechnology

Company Overview of Talon Therapeutics, Inc.

Company Overview

Talon Therapeutics, Inc., a biopharmaceutical company, develops and commercializes new and differentiated cancer therapies. Its lead product includes Marqibo (vincristine sulfate liposome injection), which is a novel sphingomyelin/cholesterol liposome encapsulated formulation of vincristine for acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. The company’s product candidates comprise Menadione topical lotion, a novel cancer supportive care product candidate, which is in a Phase II trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors in the treatment of cancers; Brakiva (topotecan liposome injection), a...

400 Oyster Point Boulevard

Suite 200

South San Francisco, CA 94080

United States

Founded in 2002

24 Employees

Phone:

650-588-6404

Fax:

650-588-2787

Key Executives for Talon Therapeutics, Inc.

Chief Executive Officer, President, Director and Member of Finance & Transactions Committee
Age: 50
Chief Financial Officer and Senior Vice President
Age: 66
Principal Accounting Officer, Director of Finance and Controller
Age: 32
Vice President of Regulatory Affairs & Quality
Age: 64
Vice President of Clinical Research
Compensation as of Fiscal Year 2014.

Talon Therapeutics, Inc. Key Developments

Talon Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013

Talon Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. The company reported a net loss of $17.5 million and deemed dividends attributable to preferred stock of $5.1 million, which when combined, resulted in a net loss applicable to common stockholders of $22.6 million, or $1.03 per basic and diluted share. This compares to a net loss of $30.5 million and deemed dividends of $5.6 million, which when combined, resulted in a net loss applicable to common stockholders of $36.1 million, or $1.66 per basic and diluted share, for the three months ended March 31, 2012. The change in fair value of Talon's preferred stockholders' rights to purchase additional shares of preferred stock contributed to $11.6 million, or $0.53 per share, of the total net loss applicable to common stockholders for the three months ended March 31, 2013. Loss from operations was $4,754,000 against $4,427,000 a year ago. Cash used in operations was $4.8 million for the three months ended March 31, 2013.

Similar Private Companies By Industry

Company Name Region
Success by Association United States
Edge BioServ, LLC United States
ProFibrix, Inc. United States
Jaleva Pharmaceuticals, LLC United States
Sanofi Pasteur VaxDesign Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Talon Therapeutics, Inc., please visit www.talontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.